Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16800914 | 0.94 | GSTP1 (0.46) | ESR1ESR2HSD17B1HSD17B2GSTP1 | |
| SCHEMBL16801167 | 0.92 | ABCG2 (0.42) | HSD17B1HSD17B2PGRGSTP1CYP1A1 | |
| SCHEMBL18159542 | 0.92 | GSTP1 (0.44) | ESR1ESR2HSD17B1HSD17B2GSTP1 | |
| SCHEMBL16801456 | 0.89 | GSTP1 (0.42) | HSD17B1HSD17B2GSTP1ALOX5CYP1A1 | |
| SCHEMBL13506943 | 0.84 | CA12 (0.40) | ESR1ESR2HSD17B1HSD17B2PGR | |
| SCHEMBL16801450 | 0.83 | ALDH1A1 (0.38) | ESR1ESR2CA1CA2CA9 | |
| SCHEMBL18159530 | 0.83 | ENPP3 (0.46) | CA1CA2CA9CA12CYP1A2 | |
| SCHEMBL18820592 | 0.82 | HPGD (0.41) | ESR1ESR2HSD17B1HSD17B2GSTP1 | |
| SCHEMBL12037292 | 0.82 | HPGD (0.41) | ESR1ESR2HSD17B1HSD17B2GSTP1 | |
| SCHEMBL16801277 | 0.82 | ALDH1A1 (0.39) | ESR1ESR2CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11917913-B2 | Substituted oxepines | MERCK PATENT GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11917913-B2 | Substituted oxepines | MERCK PATENT GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-20190280218-A1 | SUBSTITUTED OXEPINES | MERCK PATENT GMBH (DE) | 2019-09-12 | — | — | US | disclosed |
| US-10374170-B2 | Substituted oxepines | MERCK PATENT GMBH (DE) | 2019-08-06 | — | — | US | disclosed |
| US-20160308146-A1 | SUBSTITUTED OXEPINES | MERCK PATENT GMBH (DE) | 2016-10-20 | — | — | US | disclosed |
| US-20160308146-A1 | SUBSTITUTED OXEPINES | MERCK PATENT GMBH (DE) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11917913-B2 | Substituted oxepines | OXGR1, OXTR, OCIAD2 | ESR1 285/4885ESR2 497/4885HSD17B1 4820/4885 |
| US-10374170-B2 | Substituted oxepines | OXGR1, OXTR, OCIAD2 | ESR1 285/4885ESR2 497/4885HSD17B1 4820/4885 |
| US-20190280218-A1 | SUBSTITUTED OXEPINES | OXGR1, OXTR, OCIAD2 | ESR1 285/4885ESR2 497/4885HSD17B1 4820/4885 |
| US-20160308146-A1 | SUBSTITUTED OXEPINES | OXGR1, OXTR, OCIAD2 | ESR1 285/4885ESR2 497/4885HSD17B1 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.